36,766 Shares of Medtronic PLC $MDT Bought by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC acquired a new position in shares of Medtronic PLC (NYSE:MDT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 36,766 shares of the medical technology company’s stock, valued at approximately $3,173,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AMG National Trust Bank acquired a new stake in Medtronic in the third quarter valued at approximately $292,000. Moneco Advisors LLC raised its position in shares of Medtronic by 2.8% during the third quarter. Moneco Advisors LLC now owns 10,727 shares of the medical technology company’s stock worth $926,000 after purchasing an additional 289 shares during the period. Mesirow Financial Investment Management Inc. raised its position in shares of Medtronic by 16.3% during the third quarter. Mesirow Financial Investment Management Inc. now owns 9,054 shares of the medical technology company’s stock worth $781,000 after purchasing an additional 1,270 shares during the period. Woodley Farra Manion Portfolio Management Inc. raised its position in shares of Medtronic by 6.8% during the third quarter. Woodley Farra Manion Portfolio Management Inc. now owns 70,966 shares of the medical technology company’s stock worth $6,172,000 after purchasing an additional 4,536 shares during the period. Finally, Lido Advisors LLC lifted its holdings in shares of Medtronic by 28.8% in the 3rd quarter. Lido Advisors LLC now owns 99,829 shares of the medical technology company’s stock worth $8,615,000 after purchasing an additional 22,351 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares in the company, valued at $3,950,718.90. This represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael Marinaro sold 10,420 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the sale, the executive vice president owned 105,916 shares of the company’s stock, valued at approximately $10,167,936. This represents a 8.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 61,903 shares of company stock worth $5,889,203. Corporate insiders own 0.27% of the company’s stock.

Medtronic Stock Performance

Shares of MDT opened at $101.64 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. The stock has a 50 day moving average price of $93.34 and a two-hundred day moving average price of $88.46. The firm has a market capitalization of $130.01 billion, a P/E ratio of 17.76, a P/E/G ratio of 2.38 and a beta of 0.56. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same quarter last year, the company earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts forecast that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were paid a dividend of $0.72 per share. The ex-dividend date was Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Key Headlines Impacting Medtronic

Here are a few of the latest headlines about MDT:

• Positive Sentiment: Medtronic launched a micro guidewire for neurovascular procedures, expanding its product offering in that market. Article: Medtronic launches micro guidewire for neurovascular procedures
• Neutral Sentiment: A collaborative cardiac-therapy trial involving Medtronic has completed enrollment with 349 patients. Results are expected to be presented at Heart Rhythm Society 2027; a planned FDA submission depends on positive data, so the potential benefit remains uncertain. Article: Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
• Negative Sentiment: Medtronic initiated two Class II recalls affecting cardiac products. The OmniaSecure 3930M lead recall cites possible difficulties with fixation during implantation, while a CareLink SmartSync Programmer software issue may cause inaccurate estimates of implanted-device battery life. The recalls raise potential concerns about product reliability and could create costs or reputational risk, although the reports do not quantify their financial impact. Article: What Is Medtronic Facing After Two Class II Cardiac Device Recalls?

Wall Street Analysts Forecast Growth

MDT has been the subject of several research reports. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Wednesday, October 14th. Mizuho set a $115.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a report on Sunday. Wells Fargo & Company raised their price objective on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research note on Wednesday, September 2nd. Finally, Weiss Ratings raised shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 19th. Eighteen analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $102.88.

About Medtronic

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.